



Solution Sheet

# Drug Label Claim Development Accelerator

For pharmaceutical companies, drug labeling is a highly regulated and complex process. Drug labels need to provide accurate information around the safe usage of a drug without any promotional, misleading, or unsubstantiated claims.

However, the drug label content development process is often manual, disjointed, and inconsistent. The label content development teams struggle with disparate, distributed data sources with largely unstructured content. This can cause inaccuracies in label claims leading to a barrage of consequences such as delays in pending drug approvals, potential withdrawal of existing drugs from the market, higher scrutiny from regulators, and lower drug adoption with consequent cost escalations.

High amounts of disparate, unstructured data.

Lack of easy access to regulatory guidelines and labeling best practices.

Inability to integrate knowledge access into label development workflows.


## Persistent's Drug Label Claim Development Accelerator

Powered by machine learning and AWS Kendra's natural language-based intelligent search along with AWS Comprehend's text analytics capabilities, Persistent's drug label claim development accelerator helps you fast track the creation of claim labels and improve compliance by finding relevant and precise information from highly technical drug label documents and regulatory guidelines. It helps you ensure consistency and accuracy of drug safety and usage claims and thus enhances drug adoption.

With this solution in place, you can simplify claim development using:

- \ Natural language interpretation based on keyword and phrase queries
- \ Intuitive output delivering actionable insights such as answers, FAQs, relevant snippets
- \ Accuracy of results based on built-in optimization for pharmaceutical and healthcare industries
- \ Search across internal data sources such as Veeva Vault and external data sources such as the United States FDA website
- \ Filtering of results based on system and derived metadata
- \ Ability to view current results with notifications for labeling updates
- \ Guidance for query and navigation such as custom synonyms, spell-check, auto query completion, etc.

# How It Works



# Persistent's Drug Label Claim Development Accelerator in Action

## Looking up storage conditions and type of products

Search Query: Drug refrigeration requirement for paediatric

Q

1-10 of 921 results

Amazon Kendra suggested answers

**Ruzurgi**

The suspension can be stored under **refrigeration** for up to 24 hours. Discard any unused portion of the suspension after 24 hours. 2.3 Patients with Renal Impairment The recommended starting dosage of RUZURGI in **pediatric** patients weighing 45 kg or more with renal impairment (creatinine clearance 15 to 90 mL/min) is 15 mg daily taken orally in divided doses. The recommended starting dosage for **pediatric** patients weighing less than 45 kg with renal impairment is 7.5 mg daily taken orally in divided doses [see Dosage and Administration (2.1) and Use in Specific Populations (8.6)]. No dosage recommendations for RUZURGI can be made for patients with end-stage renal disease.

[https://www.accessdata.fda.gov/drugsatfda\\_docs/.../209321s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/.../209321s000lbl.pdf)

What are Amazon Kendra suggested answers? [Info](#)

Sort:

**Ruzurgi**

...The suspension can be stored under **refrigeration** for up to 24 hours. Discard any unused portion of the suspension after 24 hours. 2.3 Patients with Renal Impairment The recommended starting dosage of RUZURGI in **pediatric** patients weighing 45 kg or more with renal...

[https://www.accessdata.fda.gov/drugsatfda\\_docs/.../209321s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/.../209321s000lbl.pdf)


**Ultomiris**

...under **refrigeration** at 2°C - 8°C (36°F - 46°F) must not exceed 24 hours taking into account the expected infusion time. Once removed from **refrigeration**, administer the diluted ULTOMIRIS infusion solution within 6 hours...

[https://www.accessdata.fda.gov/drugsatfda\\_docs/.../761108s001lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/.../761108s001lbl.pdf)

# Understanding drug dosage and administration

Search Query: How is Dupixent administered for Chronic Rhinosinusitis?





1-10 of 873 results


Amazon Kendra suggested answers

[dupixent label](#)

1.3 **Chronic Rhinosinusitis** with Nasal Polyposis **DUPIXENT** is indicated as an add-on maintenance treatment in adult patients with inadequately controlled **chronic rhinosinusitis** with nasal polyposis (CRSwNP). 2 **DOSAGE AND ADMINISTRATION DUPIXENT is administered by subcutaneous injection, either by pre-filled syringe or pre-filled pen.** The **DUPIXENT** pre-filled pen is only for use in adults and adolescents aged 12 years and older. 2.1 Atopic Dermatitis Dosing in Adults The recommended dose of **DUPIXENT** for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W).



[https://s3.us-west-2.amazonaws.com/sanofi-drugs/dupixent\\_label.pdf](https://s3.us-west-2.amazonaws.com/sanofi-drugs/dupixent_label.pdf)  

What are Amazon Kendra suggested answers? [Info](#)

Sort:  



[dupixent label](#)

...asthmaticus. 1.3 **Chronic Rhinosinusitis** with Nasal Polyposis **DUPIXENT** is indicated as an add-on maintenance treatment in adult patients with inadequately controlled **chronic rhinosinusitis** with nasal polyposis (CRSwNP). 2 **DOSAGE AND ADMINISTRATION DUPIXENT is administered** by subcutaneous...

[https://s3.us-west-2.amazonaws.com/sanofi-drugs/dupixent\\_label.pdf](https://s3.us-west-2.amazonaws.com/sanofi-drugs/dupixent_label.pdf)  

[Daypro Alta](#)

...of Asthma Related to Aspirin Sensitivity A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include **chronic rhinosinusitis** complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross...

[https://www.accessdata.fda.gov/drugsatfda\\_docs/.../020776s008lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/.../020776s008lbl.pdf)  



# Conducting a comparative label analysis

1\ Select labels to compare

The screenshot shows a search interface for drug labels. At the top, there is a 'Compare Now' button. Below it, the search results for 'Tysabri' are displayed. The results include a snippet for Tysabri and two other drugs: Campath and Zinbryta. Each result has an 'Add to compare' button. The interface also shows a 'Sort: Relevance' dropdown and a 'What are Amazon Kendra suggested answers? Info' link.

2\ Choose to compare

The screenshot shows a side-by-side comparison of two drug labels: Campath and Zinbryta. The tool is titled 'LABEL COMPARISON'. It displays the full text of both labels, with differences highlighted in red. The labels contain detailed information about the drugs, including their uses, warnings, contraindications, and side effects.

3\ Side by side comparison

Improve compliance and de-risk your drug labeling processes today.

Request Demo

## About Persistent

We are a trusted Digital Engineering and Enterprise Modernization partner, combining deep technical expertise and industry experience to help our clients anticipate what's next. Our offerings and proven solutions create a unique competitive advantage for our clients by giving them the power to see beyond and rise above. We work with many industry-leading organizations world-wide including 14 of the 30 most innovative US companies, 80% of the largest banks in the US and India, and numerous innovators across the healthcare ecosystem. Our company fosters a values-driven and people-centric work environment. Our strength of over 22,500+ employees is spread over 18 different countries across the globe.

### USA

Persistent Systems, Inc.  
2055 Laurelwood Road, Suite 210  
Santa Clara, CA 95054  
Tel: +1 (408) 216 7010  
Fax: +1 (408) 451 9177  
Email: info@persistent.com

### India

Persistent Systems Limited  
Bhageerath, 402  
Senapati Bapat Road  
Pune 411016  
Tel: +91 (20) 6703 0000  
Fax: +91 (20) 6703 0008

